Desmopressin sublingual - Ferring Pharmaceuticals

Drug Profile

Desmopressin sublingual - Ferring Pharmaceuticals

Alternative Names: DDAVP Melt; FE 992026; Minirin Melt; Nocdurna; Nokdurna; Noqdirna; Noqturina

Latest Information Update: 22 Feb 2017

Price : $50

At a glance

  • Originator Ferring Pharmaceuticals
  • Class Antidiuretics; Antihaemorrhagics; Hormones; Urologics; Vasoconstrictors; Vasopressins
  • Mechanism of Action Vasopressin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Diabetes insipidus; Enuresis; Nocturia
  • Phase II Overactive bladder

Most Recent Events

  • 13 Feb 2017 The Scottish Medicines Consortium does not recommend the use of desmopressin sublingual in Nocturnal polyuria (In adults)
  • 11 Jan 2017 Ferring Pharmaceuticals initiates a phase III trial in Nocturia in Japan (NCT03051009)
  • 01 Nov 2016 Launched for Nocturia in United Kingdom (Sublingual)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top